452972-14-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoropyridine-3-boronic acid pinacol ester is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential applications in treating different diseases.
Used in Chemical Research:
In the field of chemical research, 2-Fluoropyridine-3-boronic acid pinacol ester serves as a valuable building block for the creation of novel organic molecules. Its reactivity and structural properties make it a useful tool for exploring new chemical reactions and developing innovative synthetic pathways.
Used in Material Science:
2-Fluoropyridine-3-boronic acid pinacol ester can be utilized in the development of new materials with specific properties. Its incorporation into polymers or other materials can lead to enhanced performance characteristics, such as improved stability, reactivity, or selectivity.
Used in Agrochemical Industry:
2-FLUOROPYRIDINE-3-BORONIC ACID PINACOL ESTER can also be employed in the agrochemical industry for the development of new pesticides or herbicides. Its unique chemical properties may contribute to the creation of more effective and environmentally friendly products for agricultural use.

InChI:InChI=1/C11H15BFNO2/c1-10(2)11(3,4)16-12(15-10)8-6-5-7-14-9(8)13/h5-7H,1-4H3

Upstream product

• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 372-48-5 2-fluoropyridine 
• 73183-34-3 bis(pinacol)diborane 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 36178-05-9 3-bromo-2-fluoropyridine 
• 1480-65-5 2-fluoro-5-chloropyridine 
• 5419-55-6 Triisopropyl borate 
• 174669-73-9 (2-fluoro-pyridin-3-yl)boronic acid 

Downstream Products

• 847687-37-0 3-(3-chloro-phenyl)-2-fluoro-pyridine 
• 1426414-40-5 (R)-2-fluoro-3-(1-phenyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethyl)pyridine 
• 1426414-43-8 (S)-1-(2-fluoropyridin-3-yl)-1-phenylethanol 
• 1426414-54-1 (R)-2-fluoro-3-(1-phenylethyl)pyridine 
• 1437316-70-5 Ν-((3-(3-(7-hydro-pyrrolo[2,3-d]-6-yl)pyrimidin-4-yl)pyridin-2-ylamino)-2,4-difluorobenzene-yl)propane-1-sulfonamide 
• 1380228-80-7 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)propane-1-sulfonamide 
• 1380228-04-5 N-(3-(3-(9H-purine-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl) propane-1-sulfonamide 
• 1437316-74-9 Ν-(3-(3-(8-chloro-9-(tetrahydro-2-hydropyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)propane-1-sulfonamide 
• 1437316-58-9 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-4-chloro-2-fluorophenyl)-3-fluoropropane-1-sulfonamide 
• 1093101-52-0 6-(2-fluoropyridin-3-yl)-9-(tetrahydro-2-hydro-pyran-2-yl)-9H-purine 

Relevant academic research and scientific papers

Protein kinase inhibitor and its composition and use thereof

The invention relates to compounds as shown in the general formula (I), pharmaceutical compositions containing the compounds, a method for treating diseases and disease symptoms related to abnormal activity of protein kinase by using the compounds, and medicinal use of the compounds.

Indazole Compounds as IRAK4 Inhibitors

The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z1, Z2, R1, R2, R3, ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.

Fluorine-controlled C-H borylation of arenes catalyzed by a PSiN-pincer platinum complex

An efficient, regioselective synthesis of fluorine-substituted arylboronic esters was achieved through fluorine-controlled C-H borylation of arenes with diboron catalyzed by a PSiN-platinum complex. The promising utility of the PSiN-platinum catalyst and its unique regioselectivity were demonstrated for the first time, which would complement the well-developed Ir-catalyzed C-H borylation.

INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS

The present invention provides indazole compound of formula (I), which are therapeutically useful as kinase inhibitor, particularly IRAK4 inhibitors. wherein Z1, Z2, R1, R2, R3, 'm' and 'n' have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

A catalytic borylation/dehalogenation route to o -fluoro arylboronates

A two-step Ir-catalyzed borylation/Pd-catalyzed dehalogenation sequence allows for the net synthesis of fluoroarenes where the boronic ester is ortho to fluorine. Key elements of this approach include the use of a halogen para to the fluorine to block meta Ir-catalyzed borylation and the chemoselective Pd-catalyzed dehalogenation by KF activated polymethylhydrosiloxane (PMHS).

Iridium-catalyzed C-H borylation of pyridines

The iridium-catalysed C-H borylation is a valuable and attractive method for the preparation of aryl and heteroaryl boronates. However, application of this methodology for the preparation of pyridyl and related azinyl boronates can be challenged by low reactivity and propensity for rapid protodeborylation, particularly for a boronate ester ortho to the azinyl nitrogen. Competition experiments have revealed that the low reactivity is due to inhibition of the active catalyst through coordination of the azinyl nitrogen lone pair at the vacant site on the iridium. This effect can be overcome through the incorporation of a substituent at C-2. Moreover, when this is sufficiently electron-withdrawing protodeborylation is sufficiently slowed to permit isolation and purification of the C-6 boronate ester. Following functionalization, reduction of the directing C-2 substituent provides the product arising from formal ortho borylation of an unhindered pyridine ring. This journal is the Partner Organisations 2014.

KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF

The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.

Asymmetric synthesis of 1-heteroaryl-1-arylalkyl tertiary alcohols and 1-pyridyl-1-arylethanes by lithiation-borylation methodology

The synthesis of highly enantioenriched α-heterocyclic tertiary alcohols has been achieved via lithiation-borylation of a configurationally stable lithiated carbamate and heterocyclic pinacol boronic esters followed by oxidation. Protodeboronation of the α-heterocyclic tertiary boronic esters using TBAF·3H2O or CsF gave highly enantioenriched 1-pyridyl-1-arylethanes in high er.

Directed ortho metalation-boronation and Suzuki-Miyaura cross coupling of pyridine derivatives: A one-pot protocol to substituted azabiaryls

A general method for the synthesis of azabiaryls 19a-t by a one-pot procedure involving a Directed ortho metalation (DoM)-boronation-Suzuki-Miyaura cross coupling sequence is described. Aside from the three isomeric pyridyl carboxamides 15a-c, chloro-, fl

Synthesis of novel halopyridinylboronic acids and esters. Part 2: 2,4, or 5-Halopyridin-3-yl-boronic acids and esters

This paper describes a general method for the synthesis and the isolation of novel 2,4, or 5-halopyridin-3-yl-boronic acids and esters 4, 7, 10, 13, 15. These compounds are prepared taking into account a regioselective halogen-metal exchange using nBuLi or a regioselective ortho-lithiation using lithium diisopropylamide and subsequent quenching with triisopropylborate starting from appropriate mono or dihalopyridines. All substrates studied to date provided a single regioisomeric boronic acid or ester product. Additionally, these compounds have been found to undergo Pb-catalyzed coupling with a range of arylhalides and authorize a strategy to produce new pyridines libraries.